Article
Major Histocompatibility Class-I (MHC-I) downregulation in glioblastoma is a poor prognostic factor but not a predictive indicator for treatment failure.
Pathology, research and practice - 1 Oct 2023
Butt Nadeem S, Kurdi Maher, Fadul Motaz M, Hakamy Sahar, Addas Bassam M J, Faizo Eyad, Alkhayyat Shadi, Bamaga Ahmed K, Alsinani Taghreed, Katib Yousef, Okal Fahad, Maghrabi Yazid, Sabbagh Abdulrahman J, Moshref Rana, Albalawi Sultan, Alkhotani Alaa, Mohammed Fawaz, Mulla Nasser, Baeesa Saleh
Abstract excerpt
BACKGROUND: MHC-I expression is a crucial factor in cancer immunity, and its regulations can impact tumor progression and recurrence. The mechanism through which glioblastoma use MHC-I to avoid immunosurveillance has been rarely investigated. METHODS: A retrospective cohort of 35 patients with IDH-mutant WHO-Grade 4 astrocytoma and IDH-wildtype glioblastoma were examined for MHC-I using protein and gene...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.